Table 3.
Demographic characteristics of treatment as usual (TAU) + NAT-FM and TAU participants.
| TAU + NAT-FM (n = 84) | TAU (n = 85) | t/χ2 | p | |
|---|---|---|---|---|
| General measures | ||||
| Gender, n of women (%) | 82 (97.60) | 85 (100) | 0.74 | 0.39 |
| Age, M (SD) | 54.12 (8.62) | 53.15 (9.06) | 0.32 | 0.57 |
| BMI (kg/m2), M (SD) | 27.65 (5.49) | 26.75 (5.75) | 0.48 | 0.62 |
| Years of illness, M (SD) | 19.61 (11.99) | 16.75 (9.74) | 2.92 | 0.08 |
| Married or in couple, n (%) | 57 (67.8) | 43 (50.6) | 10.41 | 0.34 |
| Cohabitating, n (%) | 38 (44.2) | 69 (81.2) | 1.84 | 0.39 |
| Secondary studies, n (%) | 38 (45.3) | 46 (54.7) | 7.45 | 0.15 |
| Labor assets, n (%) | 43 (52.0) | 40 (48.0) | 18.52 | 0.09 |
| Accreditation of disability in process, n (%) | 30 (36.0) | 54 (64.0) | 1.13 | 0.29 |
| Comorbidity with CSS, f (%) | ||||
| Chronic fatigue | 71 (84.6) | 72 (85.3) | 0.32 | 0.59 |
| Multiple chemical sensitivity | 30 (35.8) | 25 (29) | 1.72 | 0.17 |
| Irritable bowel syndrome | 38 (45.9) | 39 (46.3) | 0.08 | 0.70 |
| Migraines | 50 (59) | 49 (57.8) | 0.07 | 0.92 |
| Medication, f (%) | ||||
| Mix of more than two medications | 27 (32.9) | 41 (47.7) | 4.71 | 0.41 |
Note: The values represent means (M) and standard deviation (SD) or frequency (n) and percentages (%), in their respective order of presentation. BMI = body mass index. Significant values (p < 0.05) should be shown in bold. There are no statistically significant group differences. CSS, central sensitization syndromes.